# A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1)

> **NCT05066646** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Nanjing IASO Biotechnology Co., Ltd.** · enrollment: 132 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** CT103A

## Key facts

- **NCT ID:** NCT05066646
- **Lead sponsor:** Nanjing IASO Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-04-01
- **Primary completion:** 2022-10
- **Final completion:** 2024-06
- **Target enrollment:** 132 (ESTIMATED)
- **Last updated:** 2021-11-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05066646

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05066646, "A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05066646. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*